Dr. Juergens’ research focus has been in developmental therapeutics with a concentration on Phase I and II clinical trials including radiopharmaceutical therapies. She is a member of the Executive Committee of the Canadian Cancer Trials Group Investigational New Drug Committee. She is a member of the Cancer Research Institute’s Scientific Leadership Committee. Dr. Juergens has published her work in prominent journals including the Journal of Clinical Oncology, The New England Journal of Medicine and Cancer Discovery. She has been a principal investigator on numerous clinical trials assessing treatments in lung cancer as well as esophagogastric cancer. She is a highly sought teacher in the field of immunotherapy and has been an invited speaker across the world.
Over the past five years, Dr. Khuntia has expanded his team with global responsibilities over all aspects requiring clinical expertise, including but not limited to regulatory, research, education, product support, mergers and acquisitions. In addition to his responsibilities at Varian, he continues to hold a part-time clinical practice in Radiation Oncology in the Bay Area where he has a special interest in advanced radiation technologies, central nervous system tumors, head and neck cancer, and lung cancer. He continues to remain academically active while co-chairing multiple cooperative group trials and also serving as an examiner for the American Board of Radiology.
Dr. Khuntia earned undergraduate and medical school degrees from the University of Illinois and completed his residency in Radiation Oncology at the Cleveland Clinic. Prior to moving to the Bay Area, he was an Associate Professor at the University of Wisconsin where he served multiple leadership roles including Residency Director, Director of Radiation Oncology Outreach, and Course Director of Oncology for the Medical School.
Dr. O’Bryan-Tear obtained his MD degree from the Universities of Cambridge and London and trained in internal medicine in the UK. He joined the pharmaceutical industry in 1986 where he has spent 30 years in clinical development, medical management and commercial roles. He has held senior leadership roles in large and small pharmaceutical and biotechnology companies in both the US and Europe and has been involved in multiple product approvals. In 2009 he became Chief Medical Officer of Algeta ASA, a listed Norwegian biotechnology company developing a radiopharmaceutical for prostate cancer, which was launched worldwide in 2013. Since 2014, Dr. O’Bryan-Tear has been a retained adviser to a number of US and European biotechnology companies.
Dr. Sartor has published over 300 peer-reviewed publications and has over 20,000 citations. He has lectured widely, giving lectures on prostate cancer in 34 countries. Dr. Sartor has been a primary investigator (PI) or co-PI on multiple national and international advanced prostate cancer trials including those pivotal trial for FDA approval with samarium-153 EDTMP, cabazitaxel, and radium-223. In addition, he is currently Medical Oncology Chair of the NRG GU committee, a member of the Board of Scientific Counselors (Clinical and Epidemiology) at the National Cancer Institute, and Editor-in-Chief of the journal Clinical Genitourinary Cancer, published by Elsevier. Previously he served as Chairman of the Prostate Cancer Integration Panel for the U.S. Department of Defense. He has been Chair of five Data Monitoring Committees for Phase 3 trials that lead to FDA approval. He has served on numerous guideline and consensus committees over the years.